Answer:
Generally, K+ ions ensures re-polarization of the membrane potential. It always ensures that the neuron returns its resting state, protecting the neurons and ensuring episode of rest before the next action potential.
K+ does this by leaving the axon, making the inner layer more negative. This is resting membrane potential. Because there are many K+ channels for leakages out of the neuronal axons.
Therefore, in this scenario, he neuron will return to its resting membrane potential state which between values -50 to -75mV.
Therefore the value of the potential will be -60mV, or within the range of -50 to -60mV. This is because the neuron is is non- excitable.
Explanation:
It occurs only in cells in the reproductive structures of organisms.
Meiosis only occurs in the reproductive cells, producing gametes with half of the genetic information as the parent cell.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
The answer to the question is PCR
